505 related articles for article (PubMed ID: 20044011)
1. Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.
Goldstein EJ; Citron DM; Tyrrell KL; Warren YA
Anaerobe; 2010 Jun; 16(3):220-2. PubMed ID: 20044011
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.
Odenholt I; Walder M; Wullt M
Chemotherapy; 2007; 53(4):267-74. PubMed ID: 17595541
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of teicoplanin against Clostridium difficile.
Wongwanich S; Kusum M; Phan-Urai R
Southeast Asian J Trop Med Public Health; 1996 Sep; 27(3):606-9. PubMed ID: 9185278
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
Pituch H; Obuch-Woszczatyński P; Glinka D; Łazińska B; Meisel-Mikołajczyk F; Łuczak M
Med Dosw Mikrobiol; 2003; 55(3):253-8. PubMed ID: 14702667
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
8. In vitro effect of metronidazole and vancomycin in combination on Clostridium difficile.
Hames A; Perry JD; Gould FK
J Antimicrob Chemother; 2009 May; 63(5):1076. PubMed ID: 19240074
[No Abstract] [Full Text] [Related]
9. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
O'Connor R; Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent killing of Clostridium difficile by metronidazole and vancomycin.
Levett PN
J Antimicrob Chemother; 1991 Jan; 27(1):55-62. PubMed ID: 2050597
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
14. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
15. Editorial commentary: Vancomycin for your mother, metronidazole for your mother-in-law.
Read RC
J Infect; 2007 Dec; 55(6):483. PubMed ID: 17988743
[No Abstract] [Full Text] [Related]
16. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
[TBL] [Abstract][Full Text] [Related]
17. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic resistance of Clostridium difficile isolates.
Dworczyński A; Sokół B; Meisel-Mikołajczyk F
Cytobios; 1991; 65(262-263):149-53. PubMed ID: 1828756
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of nisin against clinical isolates of Clostridium difficile.
Bartoloni A; Mantella A; Goldstein BP; Dei R; Benedetti M; Sbaragli S; Paradisi F
J Chemother; 2004 Apr; 16(2):119-21. PubMed ID: 15216943
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
